Entrada Therapeutics (TRDA) Interest & Investment Income (2020 - 2026)

Entrada Therapeutics' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 40.91% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $13.3 million, a 32.72% decrease from a year earlier, with the FY2025 full-year figure at $15.1 million, down 22.6% from the prior year.
• Interest & Investment Income slipped to $2.6 million in Q1 2026 per TRDA's latest filing, from $3.1 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $5.8 million in Q3 2024 and bottomed at -$3.7 million in Q4 2022.
• The 5-year median for Interest & Investment Income is $3.9 million (2025), against an average of $3.0 million.
• Biggest YoY gain for Interest & Investment Income was 4377.78% in 2022; the steepest drop was 8597.73% in 2022.
• Year by year, Interest & Investment Income stood at -$3.7 million in 2022, then surged by 214.79% to $4.3 million in 2023, then advanced by 19.48% to $5.1 million in 2024, then plunged by 38.85% to $3.1 million in 2025, then fell by 16.33% to $2.6 million in 2026.
• Per Business Quant, the three latest TRDA Interest & Investment Income figures stand at $2.6 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025).